AES Annual Meeting 2025
DAY 3 | Vagus Nerve Stimulation Is a Viable Long-Term Treatment Option for Patients with Drug-Resistant Epilepsy
Vagus nerve stimulation (VNS) therapy achieved long-term reduction in seizure activity and significant improvements in quality of life in children and adults with drug-resistant epilepsy, according to a series of studies presented at the 2025 American Epilepsy Society Annual Meeting (AES 2025) in Atlanta, Georgia.
December 17, 2025
Read more
DAY 3 | Azetukalner Demonstrates Long-Term Efficacy and Safety in the Treatment of Focal Seizures
Long-term data from the open-label extension phase of the X-TOLE clinical trial showed that patients with focal onset seizures (FOS) treated with azetukalner achieved sustained reductions in seizure frequency, and a meaningful proportion of participants achieved prolonged intervals of seizure freedom of 12 months or longer. The results of the latest, 48-month interim analysis were presented at the 2025 American Epilepsy Society Annual Meeting in Atlanta, Georgia.
December 17, 2025
Read more
DAY 3 | Pediatric Patients with Focal Epilepsy Are at Risk for Clinically Significant Anxiety
A retrospective review presented at the 2025 American Epilepsy Society Annual Meeting in Atlanta, Georgia showed that children and adolescents with focal epilepsy experience a high burden of anxiety and could benefit from mental health screening and targeted interventions.
December 17, 2025
Read more
DAY 3 | Patient Reports of Seizure Frequency and Severity Are Unreliable
Ambulatory electroencephalogram (EEG) monitoring remains the most reliable source of information regarding seizure activity, according to data presented at the 2025 American Epilepsy Society Annual Meeting, in Atlanta, Georgia, which showed that patient reporting of seizure frequency and severity often lacks accuracy.
December 17, 2025
Read moreRelated Articles
DAY 1 | Individuals with Focal Epilepsy Achieved Long-Term Seizure Freedom with Azetukalner
A post-hoc analysis from the open-label extension of a phase 2b trial enrolling adults with focal onset seizures (FOS) showed that azetukalner, a Kv7 potassium channel opener, helped patients achieve long periods of seizure freedom and regain seizure control after breakthrough seizures.
December 15, 2025
Read more
DAY 1 | Depression Symptoms Increase Disease Burden for Patients with Focal Onset Seizures
Findings from a survey reflecting patient-reported outcomes showed that depression symptoms affect quality of life and increase healthcare resource utilization for individuals diagnosed with focal onset seizures (FOS), who experience a significant but underrecognized mental health burden.
December 15, 2025
Read more
DAY 1 | Minimally Invasive Laser Ablation Provides Durable Results in the Treatment of Refractory Temporal Lobe Epilepsy
Laser interstitial thermal therapy (LITT) achieved sustained reductions in seizure activity in patients with drug-resistant mesial temporal lobe epilepsy, according to an analysis featured at the 2025 American Epilepsy Society Annual Meeting, in Atlanta, Georgia.
December 15, 2025
Read more
DAY 1 | Patients and Providers Struggle with the Complex Titration Schedules of Anti-Seizure Medications
The titration of anti-seizure medications presents a complex clinical challenge for patients with focal epilepsy and the physicians who manage their care, according to findings from a study presented at the 2025 American Epilepsy Society Annual Meeting, in Atlanta, Georgia.
December 15, 2025
Read more
DAY 2 | Telehealth Intervention Improves Access to Care for Individuals with Epilepsy and Cognitive Impairment
A hub-and-spoke model for epilepsy self-management led to a steady increase in physician referrals over 2 years, providing patients with epilepsy with options for self-management outside traditional clinical settings, according to a study designed to evaluate the effects of the HOBSCOTCH Institute Translational Network (HITN) project.
December 16, 2025
Read more
DAY 2 | Complex Surgical Procedures and Associated Syndromes May Delay Surgery for Children with Epilepsy
A retrospective analysis of children who underwent surgical procedures for epilepsy at the University of California, Los Angeles (UCLA) Mattel Children’s Hospital showed that underlying syndromes and the type of planned surgical procedmay lead to surgical delays in this population.
December 16, 2025
Read more
DAY 2 | Depression Complicates the Management of Newly Diagnosed Epilepsy
Patients with newly diagnosed epilepsy and depression are more likely to discontinue or switch first-line therapies than those without depressive symptoms, resulting in an increased risk of treatment failure, according to a study presented at the 2025 American Epilepsy Society Annual Meeting (AES 2025) in Atlanta, Georgia.
December 16, 2025
Read more
© 2026 Wolters Kluwer. All right reserved.